<DOC>
	<DOC>NCT01318837</DOC>
	<brief_summary>This study is to evaluate change of over active bladder symptom scores (OABSS) between, before and after solifenacin treatment to OAB subjects.</brief_summary>
	<brief_title>A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Symptoms of OAB for 3 months or longer At least 1 urgency episode in last 3 days Symptoms of OAB as verified by the screening 3day bladder diary, defined by: a. Number of micturition ≥8 times/day b. Number of urgency episodes in 3 days ≥3 Significant stress incontinence or mixed stress/urge incontinence Subject with indwelling catheters or practicing intermittent selfcatheterization Symptomatic urinary tract infection, chronic inflammation Diabetic neuropathy Subjects who are prohibited from taking solifenacin as contraindications Drug or nondrug treatment for OAB was started, quitted or changed in 4 weeks Participation in any clinical trial in 30 days except for Part1 of RESORT Diabetic neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>OABSS</keyword>
	<keyword>IPSS</keyword>
	<keyword>PPBC</keyword>
	<keyword>Solifenacin</keyword>
</DOC>